

Abstract

Background

Pegfilgrastim's role in reducing febrile neutropenia (FN) risk in patients with colorectal cancer (CRC) receiving chemotherapy plus bevacizumab was not previously evaluated in a prospective study. This phase 3, double-blind trial evaluated efficacy of pegfilgrastim vs placebo in reducing grade 3/4 FN incidence in patients with advanced CRC receiving bevacizumab in combination with first-line chemotherapy (FOLFOX or FOLFIRI).

Patients and Methods

Patients ≥ 18 years of age with locally advanced/metastatic CRC were randomized 1:1 to placebo or 6-mg pegfilgrastim ~24 hours after receiving chemotherapy plus bevacizumab every 14 days. The study treatment period included 4 cycles, but patients could continue treatment for up to 60 months. The primary endpoint was grade 3/4 FN incidence in the first 4 cycles. Secondary endpoints included objective response rate (ORR), overall survival (OS), and progression-free survival (PFS) analyzed at the end of the long-term follow-up period.

Results

A total of 845 patients were randomized between November 2009 and January 2012 (422, pegfilgrastim; 423, placebo). Pegfilgrastim significantly reduced grade 3/4 FN incidence in the first 4 treatment cycles (pegfilgrastim, 2.4% [95% CI: 1.1–4.3] vs placebo, 5.7% [95% CI: 3.7–8.3]; odds ratio [OR] 0.41; $P=0.014$). No significant differences were observed between the two arms in ORR (OR 1.15, $P=0.330$), and OS and PFS (hazard ratio 0.94, $P=0.440$ and 0.93, $P=0.300$, respectively).

Conclusion

Pegfilgrastim reduced FN incidence in patients with advanced CRC receiving chemotherapy and bevacizumab. Administration of pegfilgrastim was tolerable and did not negatively impact tumor response or survival in this patient population.

Keywords

- Pegfilgrastim;
- colorectal cancer;
- febrile neutropenia;
- overall survival

Funding: This work was supported by Amgen Inc.

Trial registration: This trial was registered at ClinicalTrials.gov: NCT00911170 on May 21, 2009.

Conflict Of Interest

Zandra Klippel, Maureen Reiner, and Phuong Khanh Morrow are employees and stockholders of Amgen Inc. Sadie Whittaker is a stockholder of Amgen Inc. Sadie Whittaker and Mi Rim Choi were employees and stockholders of Amgen Inc. at the time of the study. Tamas Pinter participated in an advisory board and/or was a consultant to Pfizer, Novartis, and Roche. Alvydas Cesas received research funding from Amgen Inc. Adina Croitoru received research funding and was a consultant to Amgen Inc. All remaining authors have declared no conflicts of interest.

Correspondence to: Dr. Tamás Pinter, Department of Oncoradiology, Petz Aladár County Teaching Hospital Győr, Vasvári Pál 7/a H-9024 Győr, Hungary. Phone: +36-20-331-0075; Fax: +36-96-503-324;

*

Currently at Sunderby Hospital, Luleå, Sweden

© 2016 Elsevier Inc. All rights reserved.

Note to users:

Accepted manuscripts are Articles in Press that have been peer reviewed and accepted for publication by the Editorial Board of this publication. They have not yet been copy edited and/or formatted in the publication house style, and may not yet have the full ScienceDirect functionality, e.g., supplementary files may still need to be added, links to references may not resolve yet etc. The text could still change before final publication. Although accepted manuscripts do not have all bibliographic details available yet, they can already be cited using the year of online publication and the DOI, as follows: author(s), article title, Publication (year), DOI. Please consult the journal's reference style for the exact appearance of these elements, abbreviation of journal names and use of punctuation.

When the final article is assigned to volumes/issues of the Publication, the Article in Press version will be removed and the final version will appear in the associated published volumes/issues of the Publication. The date the article was first made available online will be carried over.